Apellis Pharmaceuticals, Inc. APLS incurred third-quarter 2024 loss of 46 cents per share, wider than the Zacks Consensus Estimate of a loss of 32 cents. The company had incurred a loss of $1.17 ...

The pharmaceutical company's two main products, Syfovre and Empaveli, did not meet sales projections. Syfovre generated $152 million, falling short by $15.7 million, while Empaveli brought in $24.6 ...

The firm thinks Q3 was validating for its view of a slowing GA market and that Syfovre estimates need to be reset. Wells believes incrementally negative commentary on pricing and more gradual ramp ...

November 7, 2024 • When people can't sleep, they tend to take extreme measures to correct the issue. But that only makes sleep problems worse, say experts. Here are 5 bad habits to avoid when ...

In connection with the Empaveli/Syfovre Transaction completed in 2022, the Trust acquired other current assets. The related amortization expense is recorded in other operating expenses.

Apellis Provides Update on Review of Rare Safety Events with SYFOVRE Apellis Pharmaceuticals, Inc. (Nasdaq: NASDAQ:APLS) (“the Company”) today provided an update on its review of rare events ...

That approval set up a market clash with Apellis Pharma's complement C3 inhibitor Syfovre (pegcetacoplan), which was cleared a few months earlier. There are currently no approved treatments ...

Apellis’ application to market its complement C3 inhibitor Syfovre (pegcetacoplan) to treat geographic atrophy (GA) – a sight-robbing condition that accompanies age-related macular ...